UNSPSC 51161564: Ablukast sodium

This classification denotes an anti-asthmatic agent with the molecular formula C28H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37BXZ0J2RT, chemically known as 2h-1-benzopyran-2-carboxylic acid, 6-acetyl-7-((5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl)oxy)-3,4-dihydro-, monosodium salt, ( -); but more generally known as ablukast sodium, which bears US NIH Compound Identifier 57108. Most nations, for tariff and trade purposes, schedule ablukast sodium under HS 29329985 and SITC 51569.

As of Q4 2014, ABLUKAST SODIUM remains US FDA's Preferred Term for this commodity. Ablukast sodium bears US NLM identifiers UMLS ID C2827073 and NCI Concept Code C83514. SMILES: CCCC1C(CCC(C1O)C(=O)C)OCCCCCOC2CC3C(CC2C(=O)C)CCC(O3)C(=O)[O-].[NA+].

UNSPSC 51161564 Ablukast sodium is a Commodity code covering procurement of this leukotriene-receptor antagonist pharmaceutical product by state and local health agencies, hospitals, and institutional healthcare systems. The code addresses acquisition of ablukast sodium as a pharmaceutical input for respiratory and allergic conditions, typically as part of formulary management or institutional bulk purchasing for patient care delivery. State and local health departments, hospital systems, and public health agencies use this code when procuring pharmaceutical inventory to support clinical operations.

The source provided contains no recent state or local contract opportunities under this code and does not identify issuing bodies, geographic activity, or representative solicitations for ablukast sodium procurement. Without posted opportunities in the recent-opportunities dataset, no characterization of current market activity, buyer concentration, or geographic spread can be drawn.